MediGene AG Achieves Positive Results With RhuDex(R) In Clinical Phase IIa Trial

Martinsried/Munich June 24, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the drug candidate RhuDex® for the treatment of rheumatoid arthritis. Apart from positive safety data and the good adsorption after oral administration, first indication of biological activity of RhuDex® was observed. The data regarding pharmacokinetics (behaviour and distribution of the drug in the body) and bioavailability (concentration of the active ingredient in the blood after drug administration) obtained in the trial will, among other aspects, form the basis of the design of a comprehensive phase II trial of RhuDex® which is scheduled for initiation in 2009, as announced earlier. A new pharmaceutical form of RhuDex® as a tablet has been developed in the meantime and shall provide additional treatment facilitation for the patients.